Overview

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and FLAG-IDA chemotherapy schedule (FLAG-QUIDA regimen) in first relapsed/refractory AML (acute myeloid leukemia) patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

PETHEMA Foundation

Collaborators:

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Syntax for Science, S.L

Treatments:

Cytarabine
Fludarabine
Idarubicin